HUTCHMED (China) Ltd Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China Call Transcript
Good day, and thank you for standing by. Welcome to the HUTCHMED Licensing to Takeda Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your first speaker today, Mark Lee. Please go ahead.
()-&
Thank you, Nadia. And welcome, everybody. Good morning, good afternoon and good evening, and we're excited to talk to you today about this partnership we have with Takeda for fruquintinib development and commercialization outside of China.
Today, we'll have a few -- because with us, of course, Dr. Weiguo Su, our Chief Executive Officer and Chief Scientific Officer; Mr. Johnny Cheng, our Chief Financial Officer; Dr. Karen Atkin, our Chief Operating Officer; and Dr. Michael Shi, our Head of R&D and Chief Medical Officer.
We also have for questions and answers, Pallavi Garg, the Head of Global Oncology
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
